Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes
|
|
- Paul Blair
- 5 years ago
- Views:
Transcription
1 Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes DAVID S. H. BELL CHAIRMAN BELL, DSH. DIABETES CARE(2003)26:
2 Speaker s Bureau: AstraZeneca Novo Nordisk Janssen
3 Etiology and Prevalence of Diabetic Heart Failure David S. H. Bell MB, FACE, FRCP, FRCPS(Can), FRCP (Ed) Professor of Medicine (Retired) University of Alabama Southside Endocrinology Birmingham, AL
4
5 The Rest of the Story? Two CVD Disorders 1) Disorders of perfusion due to atherosclerosis 2) Disorders of cardiac structure and function due to LVH and LV dysfunction
6 Congestive Heart Failure Is More Common in Patients With Type 2 Diabetes Prevalence Rate per No Diabetes Diabetes Incidence Rate per < < Age at Baseline Nichols, GA, et al. Diabetes Care. 2001; 24:
7 DIABETES STATUS AND OUTCOMES IN HEART FAILURE Kristensen, SL. Circ Heart Fail(2016)9(1)e0025
8 CHEMO-RELATED CARDIOTOXICITY 83 PATIENTS (54 BREAST, 20 LYMPHOMA, 9 GASTRIC) PRESENCE OF REDUCED E# AND GLOBAL LONGITUDINAL STRAIN IN DIABETIC SUBJECTS Gomez, AC. Euro Echo-Imaging(2016) Leipzig Germany Dec 7-10.
9 Cardiotoxic Triad Diabetic cardiomyopathy Hypertension Myocardial ischemia Macrovascular Microvascular No lactate increase during atrial pacing Endothelial dysfunction leading to vasconstriction, reperfusion injury, and myocardial fibrosis Endothelial dysfunction leading to vessel permeability and myocardial fibrosis Genda A et al. Clin Cardiol. 1986;9: Ahmed SS et al. Am Heart J. 1975;89: Factor SM et al. The Diabetic Heart. 1991;89:101.
10 Diabetic Cardiomyopathy 1) Diastolic Dysfunction 30% by Echo 52% - 60% using pulse waved doppler examinations during second stage of valsalva maneuver Frequency proportional to A 1C Degree proportional to level of microalbuminuria Redfield MM JAMA (2003) 289: Poirier P Diabetes Care (2001) 24:5-10 Devereux JB Circulation (2000) 101: Liu JE J Am Coll Cardiol (2003) 42:2022-8
11 MECHANISMS FOR DIABETIC CARDIOMYOPATHY (2) 4) BIOCHEMICAL - Ca AND K CHANNELS - Na/Ca EXCHANGERS - Ca BINDING PROTEINS - MITOCHONDRIAL Ca UNIPORTER 5) UPREGULATION OF RAS 6) OXIDATIVE STRESS 7) GLYCATION OF PROTEINS 8) ACTIVATION OF PKC
12 MECHANISMS FOR DIABETIC CARDIOMYOPATHY (1) 1) ENDOTHELIAL DYSFUNCTION 2) AUTONOMIC NEUROPATHY - IMPAIRED VASODILATION TO SYMPATHETIC RESPONSE - IMPAIRED CONTRACTILITY 3) METABOLIC - GLUCOSE LACTATE METABOLISM - ENHANCED FFA METABOLISM LIPID ACCUMULATION LIPOTOXICITY APOPTOSIS
13 CERAMIDE MYOCARDIAL APOPTOSIS IR INSULIN LVH GLUCOSE MICROVASCULAR GLYCOSOCATION FIBROSIS PROPOSED ETIOLOGY OF DIABETIC CARDIOMYOPATHY
14 LV Hypertrophy and Diabetes Framingham Study: Women with diabetes had a ventricular mass 22% greater than their nondiabetic peers 1 Tayside Study: LV hypertrophy present in 32% of normotensive patients with type 2 diabetes independent of CAD, ACEIs, or HTN 2 Echocardiographic study of 371 subjects with type 2 diabetes showed that 71% had LV hypertropy 3 Relative risk of death in African Americans with*,4 : LV hypertrophy: 2.4 LV systolic dysfunction (EF 45%): 2.0 Coronary artery disease: 1.6 *Based on cohort study from a hospital registry with a mean follow-up of 5 years. 26.1% of those studied had diabetes. 1. Galderisi M. Am J Cardiol. 1991;68: Struthers AD. Lancet. 2002;359: Dawson A et al. Diabetologia. 2005;48: Liao Y. JAMA. 1995;273:
15 Myocardial Remodeling Sustained Increase in Cardiac Volume Hyperinsulinemia Hyperglycemia Connelly CM, et al. Circulation. 1991;84: Ohya Y, et al. Hypertension. 1996;27:
16 Cardiac Remodeling Gothic Arch Dysfunction Roman Arch Fibrosis Normal Left Ventricle Reversal of Remodeling Remodeled / Dilated Left Ventricle Reduced Wall Compliance Increased Wall Stress Increased Filling Pressure Coghlan HC, Coghlan L. Semin Thorac Cardiovasc Surg. 2001;13: Decreased Contractile Performance
17 Progression of Cardiovascular Disease Coronary artery disease Arrhythmia Hypertension Left ventricular injury Pathologic remodeling LV dysfunction Death Diabetic Cardiomyopathy Diabetes (Metabolic Syndrome) (Hypertrophy, Myocyte Loss, Fibrosis) Neurohormonal activation Pump failure
18 TRACE: Effect of Trandolapril on CHF Progression after Acute MI Diabetics Non-Diabetics Placebo Placebo 0.2 Trandolapril Trandolapril Relative risk, 0.38 p < Years Relative risk, 0.81 p = Years TRACE JACC 1999; 34; 83-89
19 Mortality Risk Reduction (%) Meta-Analysis of COREG Placebo-Controlled Outcomes Trials (HF or Post-MI LVD): Mortality All Patients Patients Without DM Patients With DM P.0001 P.0001 P=.029 Treatment by Diabetes Interaction P=NS Meta-analysis of trials include: US Carvedilol Trials, ANZ Heart Failure study, CAPRICORN, and COPERNICUS. All patients with LVD in these trials were included in the meta-analysis. Bell DSH et al. Curr Med Res Opin. 2006;22:
20 VALSARTAN/SACUBITRIL SUPRESSION OF RAS SACUBITRIL INHIBITS NEUTRAL ENDOPETIDASE WHICH DEGRADES VASOACTIVE PEPTIDES (ANP, BNP) SUPRESSION ENDOGEOUS COUNTER BALANCE TO RAS INHIBITION CONSISTENT REDUCTION OF HEART, WEIGHT AND CARDIAC FIBROSIS INDEPENDENT OF BP CONTROL REDUCES PROTEINURIA, RETINOPATHY IN DIABETIC SUBJECTS IN PARADIGM-HF TRIAL WITH REDUCED EF BETTER THAN ENALARIL FOR DECREASING MORTALITY AND HOSPITALIZATION FOR HF ACROSS THE HbA1c SPECTRUM Uiyl,E. Curr Hypertens Rep(2016)18(12)86. Kristensen, SL. Circ Heart Fail(2016)9(1)
21 TREATMENT EFFECTS OF SACUBITRIL/VALSARTAN VERSUS ACE INHIBITOR RR 95% CI HF HOSP/CV DEATH CV DEATH HF HOSP MORTALITY (ALL CAUSE) CLINICAL SCORE Kristensen, SL. Circ Heart Fail(2016)9(1)e
22 HEART FAILURE normal EJECTION FRACTION (HFnEF) 40%-60% ADMISSIONS WITH HF DIABETES 45% OTHER FACTORS AGE, FEMALE HYPERTENSION, OBESITY, AF, CAD Mentz, RJ. J Am Coll Cardiol(2014)64(21)
23 Diastolic Dysfunction Documented in young diabetic patients, most of whom have type 1 DM 30% incidence on standard echocardiography With more rigorous Doppler methods, early diastolic dysfunction can be diagnosed Diastolic dysfunction seen in 52% of diabetic patients in Olmstead County, Minnesota Diastolic dysfunction seen in 60% of diabetic patients in Quebec, Canada Discharge diagnosis of idiopathic cardiomyopathy more common in the diabetic patient Schannwell CM et al. Cardiology. 2002;98: Di Bonito P et al. Diabet Med. 1996;13: Redfield MM et al. JAMA. 2003;289: Poirier P et al. Diabetes Care. 2001;24:5-10. Bertoni AG et al. Diabetes Care. 2003;26:
24 HPnEF 1) LARGE CLINICAL TRIALS HAVE NOT SHOWN LIMITED EVIDENCE OF CLINICAL BENEFIT 2) AGGRESSIVE MANAGEMENT OF CONTRIBUTING FACTORS HTN, AF, MYOCARDIAL ISCHEMIA AND SLEEP APNEA BENEFICIAL 3) DIURETICS TO IMPROVE DYSPNEA 4) AVOID UNBENEFICIAL THERAPIES 5) SALT AND WATER RESTRICTON, EXERCISE Basaraba JE, Barry AR. Pharmacotherapy(2015)35(4)
25 LOWERING LEFT ATRIAL PRESSURE IN HFnEF (1) 1) THERAPEUTIC OPTIONS LIMITED 2) INCREASED LEFT ATRIAL PRESSURE ESPECIALLY DURING EXERCISE IS A KEY CONTRIBUTOR TO SYMPTOMS 3) 8 mm PERMANENT SHUNT IN ATRIAL SEPTUM TO LOWER LEFT ATRIAL PRESSURE 4) AT 30 DAYS LV FILLING PRESSURE REDUCED FROM 19.7 TO 14.2 mmhg (p=0.005) 5) NYHA CLASS IMPROVED IN 63.6% OF SUBJECTS 6) NO PULMONARY HYPERTENSION Søndergaard, L. Eur J Heart Fail(2014)16(7)
26 DIAGNOSIS AND Rx OF DIABETIC HF SIGNS AND SYMPTOMS BNP/PRO-BNP ECHO <40% >40% Rx UNDERLYING PATHOLOGY (HTN+HF) REVASCULARISATION EXERCISE SLEEP ANEA B-BLOCKERS ALDOSTEONE BLOCKADE VALSARTAN/SACUBITRIL (ENTRESTO)
27 THE END???
Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes
Heart Failure: The Frequent, Forgotten and often Fatal Complication of Type 2 Diabetes DAVID S. H. BELL CHAIRMAN BELL, DSH. DIABETES CARE(2003)26:2433-41. The Rest of the Story? Two CVD Disorders 1) Disorders
More informationDiabetes and the Heart
Diabetes and the Heart Association of Specialty Professors April 4, 2013 Jorge Plutzky, MD Co-Director, Preventive Cardiology Director, The Lipid Clinic Cardiovascular Division Brigham and Women s Hospital
More informationDIASTOLIC HEART FAILURE
DIASTOLIC HEART FAILURE M Mohsen Ibrahim, MD Alexandria, Proposed Criteria for Diastolic Heart Failure ESC Working Group (EHJ 1998) CHF signs/symptoms EF 45% Hemodynamic or echo evidence of diastolic dysfunction
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationDiabetes and Heart Failure
Diabetes and Heart Failure A common and fatal combination A Aspects on epidemiology, prognosis diagnosis and therapy Lars Rydén Department of Medicine Karolinska Institutet Stockholm, Sweden Diabetes and
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationHEART FAILURE. The Frequent and Often Fatal Complications of Diabetes
HEART FAILURE The Frequent and Often Fatal Complications of Diabetes David S.H. Bell, M.B., FRCP (Ed), FRCPS (Canada), FACP, FACE The University of Alabama Medical School Birmingham, Alabama USA Increased
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHeart Failure with Preserved Ejection Fraction: Mechanisms and Management
Heart Failure with Preserved Ejection Fraction: Mechanisms and Management Jay N. Cohn, M.D. Professor of Medicine Director, Rasmussen Center for Cardiovascular Disease Prevention University of Minnesota
More informationPathophysiology and Diagnosis of Heart Failure
Pathophysiology and Diagnosis of Heart Failure Francesco Paneni, MD, PhD, FESC Cardiology Unit Karolinska University Hospital Stockholm, Sweden Cardiology University Hospital Zurich Switzerland francesco.paneni@gmail.com
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationOutline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies
Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the
More informationManagement of Heart Failure in Adult with Congenital Heart Disease
Management of Heart Failure in Adult with Congenital Heart Disease Ahmed Krimly Interventional and ACHD consultant King Faisal Cardiac Center National Guard Jeddah Background 0.4% of adults have some form
More informationHFpEF: How to optimise management
HFpEF: How to optimise management Burkert Pieske M.D. Berlin, Germany Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, and Department of Internal
More informationPrevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient
Prevention of Atrial Fibrillation and Heart Failure in the Hypertensive Patient The Issue of Primary Prevention of A.Fib. (and Heart Failure) and not the Prevention of Recurrent A.Fib. after Electroconversion
More informationDominic Y. Leung, MBBS, PhD; Melissa Leung, MBBS, PhD Department of Cardiology, Liverpool Hospital, University of New South Wales, Sydney, Australia
Original Article Heart Metab. (2017) 73:18-23 Early detection of left ventricular dysfunction in diabetes Dominic Y. Leung, MBBS, PhD; Melissa Leung, MBBS, PhD Department of Cardiology, Liverpool Hospital,
More informationHeart 101. Objectives. Types of Heart Failure How common is HF? Sign/Symptoms, when to see a doctor? Diagnostic testing
EXAMING HEART FAILURE: HOW TO RECOGNIZE AND TREAT THE WEAK HEART What is Heart Failure? Treatment of Heart Failure End Stage Heart Failure Munir S. Janmohamed M.D. FACC Assistant Clinical Professor of
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationHeart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)
Thessaloniki, May 27, 2017 Heart Failure with Preserved Left Ventricular Ejection Fraction Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University
More informationDisclosures. Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin
Disclosures Speaker s bureau: Research grant: Advisory Board: Servier International, Bayer, Merck Serono, Novartis, Boehringer Ingelheim, Lupin Servier International, Boehringer Ingelheim Servier International,
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationHFNEF. Heart Failure is
HFNEF Bijoy K. Khandheria, MD. FASE, FACP, FACC FESC Professor of Medicine University of Wisconsin Director. Echocardiography Services Aurora Health Care No conflicts or off label use CP1173868-1 Heart
More informationIndex. Note: Page numbers of article titles are in boldface type.
Heart Failure Clin 2 (2006) 101 105 Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, 30 31 Adipokines, cardiovascular events related to, 6 Advanced
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationHow to Evaluate the Heart of Elderly Patients
How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer
More informationHeart Failure Management Update
Heart Failure Management Update Rafique Ahmed, MD, PhD, FACC, FCPS Consultant Cardiac Electrophysiologist Baltimore, Maryland, USA Heart Failure - Definition The situation when the heart is incapable of
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationThe Therapeutic Potential of Novel Approaches to RAAS. Professor of Medicine University of California, San Diego
The Therapeutic Potential of Novel Approaches to RAAS Inhibition in Heart Failure Barry Greenberg, M.D. Professor of Medicine University of California, San Diego Chain of Events Leading to End-Stage Heart
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationChemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY
Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationEchocardiographic study of left ventricular diastolic dysfunction in normotensive asymptomatic type II diabetes mellitus
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 7 Ver. VI (July. 2015), PP 39-43 www.iosrjournals.org Echocardiographic study of left ventricular
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationΒασιλική Κατσή. Καρδιολόγος ΓNA Ιπποκράτειο
Βασιλική Κατσή Καρδιολόγος ΓNA Ιπποκράτειο 40 διαφάνειες ίσως Και πρέπει και δικαιούνται ΣΥΧΝΟΤΕΡΑ 76-96% 3343 men and 4199 women followed for 25 years, no HF at baseline BP (mm Hg)
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More informationMedical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece
Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece Disclosures Grants: ALARM investigator received research grants
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationValue of echocardiography in chronic dyspnea
Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationSleep Apnea and Heart Failure
Sleep Apnea and Heart Failure Micha T. Maeder, MD Cardiology Division Kantonsspital St. Gallen Switzerland micha.maeder@kssg.ch Sleep Disordered Breathing (SDB) in HFrEF 700 HFrEF patients (LVEF
More informationHeart Failure with Preserved Ejection Fraction (HFpEF): Natural History and Contemporary Management
Heart Failure with Preserved Ejection Fraction (HFpEF): Natural History and Contemporary Management Jason L. Guichard, MD, PhD Greenville Health System Department of Medicine, Carolina Cardiology Consultants
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationAn Update in Heart Failure
An Update in Heart Failure Dr Peter Dias Cardiologist Heartswest AHFCTS Fiona Stanley Hospital Disclosures No financial, industry, pharma disclosures I am not an endocrinologist References Heart disease
More informationRestrictive Cardiomyopathy
ESC Congress 2011, Paris Imaging Unusual Causes of Cardiomyopathy Restrictive Cardiomyopathy Kazuaki Tanabe, MD, PhD Professor of Medicine Chair, Division of Cardiology Izumo, Japan I Have No Disclosures
More informationValvular Guidelines: The Past, the Present, the Future
Valvular Guidelines: The Past, the Present, the Future Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief,
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationΔυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;
Ελληνική Καρδιολογική Εταιρεία Σεμινάρια ομάδων εργασίας Θεσσαλονίκη, 8-10 Φεβρουαρίου 2018 Ομάδα εργασίας Ηχωκαρδιολογίας Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ; ΑΓΑΘΗ-ΡΟΖΑ
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationThe right heart: the Cinderella of heart failure
The right heart: the Cinderella of heart failure Piotr Ponikowski, MD, PhD, FESC Medical University, Centre for Heart Disease Clinical Military Hospital Wroclaw, Poland none Disclosure Look into the Heart
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationEjection Fraction in Patients With Chronic Heart Failure. Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction
Diastolic Heart Failure or Heart Failure with Preserved Ejection Fraction Keith Miller MD Diastolic Heart Failure Risk Factors Common Risk Factors Aging Female gender Obesity Hypertension Diabetes mellitus
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationPreserved EF with heart failure (HF pef) 50% 5 year survival. Both have type 2 diabetes Both have hypertension Both have normal ejection fractions
Research companies Government / University research Preserved EF with heart failure (HF pef) 50% 5 year survival Both have type 2 diabetes Both have hypertension Both have normal ejection fractions Introduction
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationDiastolic Function Overview
Diastolic Function Overview Richard Palma BS, RDCS, RCS, APS, FASE Director and Clinical Coordinator The Hoffman Heart and Vascular Institute School of Cardiac Ultrasound None Disclosures Learning Objectives
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationNew Strategies For Treating Patients With Chronic Heart Failure
New Strategies For Treating Patients With Chronic Heart Failure Barry Greenberg MD Professor of Medicine Director, Advanced Heart Failure Treatment Program University of California, San Diego Disclosures
More informationLeft ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy
Left ventricular diastolic function and filling pressure in patients with dilated cardiomyopathy Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania My conflicts of interest: I have
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationDialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy
Dialysis-Dependent Cardiomyopathy Patients Demonstrate Poor Survival Despite Reverse Remodeling With Cardiac Resynchronization Therapy Evan Adelstein, MD, FHRS John Gorcsan III, MD Samir Saba, MD, FHRS
More informationΜαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό
Μαρία Μπόνου Διευθύντρια ΕΣΥ, ΓΝΑ Λαϊκό Diastolic HF DD: Diastolic Dysfunction DHF: Diastolic HF HFpEF: HF with preserved EF DD Pathophysiologic condition: impaired relaxation, LV compliance, LV filling
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationPathophysiology: Heart Failure. Objectives
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Clinical Medicine Objectives At the conclusion of this seminar, learner will be able to: 1. Define heart failure as a clinical
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationChoosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman
Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease Greg Wellenius Joel Kaufman Framework for Choosing Subclinical Outcomes To Study What clinical outcomes
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationHYPERTENSION AND HEART FAILURE
HYPERTENSION AND HEART FAILURE Kenya Cardiac Society Symposium Feb 2017 Dr Jeilan Mohamed No conflict of interests . Geoffrey, 45 yr old hypertensive office worker male from Nairobi, has just watched his
More informationΜυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα
Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of
More informationDr Dinna Soon. Consultant Cardiologist, Department of Cardiology. GP symposium 2 April 2016
Dr Dinna Soon Consultant Cardiologist, Department of Cardiology GP symposium 2 April 2016 Case presentation 76 years old male, chronic smoker, hypertension, previous MI 3/7 SOB and chest tightness BP
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationSevere Left Ventricular Dysfunction: Evolving Revascularization Strategies
Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern
More informationLEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR?
LEFT BUNDLE BRANCH BLOCK- BENIGN OR A HARBINGER OF HEART FAILURE? PROGNOSTIC INDICATOR? Juan Cinca Department and Chair of Cardiology Hospital de la Santa Creu i Sant Pau Universitat Autònoma de Barcelona
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationAtrial dysfunction and chronotropic incompetence
Pathophysiology of heart failure with preserved ejection fraction Atrial dysfunction and chronotropic incompetence Vojtech Melenovsky IKEM, Prague, Czech Republic DECLARATION OF CONFLICT OF INTEREST :
More informationGoing to high altitude with heart disease. Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern
Going to high altitude with heart disease Prof. Dr. med. Stefano Rimoldi High Altitude Medicine Inselspital Bern stefano.rimoldi@insel.ch There are very few studies on patients with heart disease going
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationWhat s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine
What s new in heart failure management? Yonsei Cardiovascular Center Yonsei University College of Medicine Current Guideline of Treatment Asymptomatic Mild/Mod Severe Refractory Correct Cause: Arrhythmias
More informationHeart Failure Dr ahmed almutairi Assistant professor internal medicin dept
Heart Failure Dr ahmed almutairi Assistant professor internal medicin dept (MBBS)(SBMD) Introduction Epidemiology Pathophysiology diastolic/systolic Risk factors Signs and symptoms Classification of HF
More informationInnovation therapy in Heart Failure
Innovation therapy in Heart Failure P. Laothavorn September 2015 Topics of discussion Basic Knowledge about heart failure Standard therapy New emerging therapy References: standard Therapy in Heart Failure
More informationThe role of remote monitoring in preventing readmissions after acute heart failure
The role of remote monitoring in preventing readmissions after acute heart failure October 20, 2017 Randall C Starling MD MPH FACC FAHA FESA FHFSA Professor of Medicine Kaufman Center for Heart Failure
More informationObjectives. Let s start at the beginning 10/28/2014. What is Heart Failure? Understanding Heart Failure with Preserved LV Systolic Function
Understanding Heart Failure with Preserved LV Systolic Function Eric Ernst, MD Medical Director C.O.R.E. Clinic Objectives Clarify the terminology surrounding right heart failure and diastolic heart failure
More information